CW Advisors LLC Has $15.56 Million Position in Johnson & Johnson $JNJ

CW Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 43.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 101,880 shares of the company’s stock after selling 76,836 shares during the period. CW Advisors LLC’s holdings in Johnson & Johnson were worth $15,562,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Smart Money Group LLC increased its stake in shares of Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after purchasing an additional 407 shares during the last quarter. United Bank raised its holdings in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Bouchey Financial Group Ltd lifted its stake in shares of Johnson & Johnson by 5.6% in the 1st quarter. Bouchey Financial Group Ltd now owns 7,569 shares of the company’s stock valued at $1,255,000 after purchasing an additional 404 shares during the last quarter. Finally, Intrust Bank NA boosted its holdings in Johnson & Johnson by 7.6% in the first quarter. Intrust Bank NA now owns 21,787 shares of the company’s stock worth $3,613,000 after purchasing an additional 1,545 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.0%

Shares of JNJ stock opened at $205.36 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $207.81. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $494.77 billion, a PE ratio of 19.82, a price-to-earnings-growth ratio of 2.29 and a beta of 0.36. The stock has a 50 day moving average of $193.11 and a 200-day moving average of $174.71.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. UBS Group raised their target price on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Royal Bank Of Canada restated an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Barclays boosted their price objective on shares of Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $202.10.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.